Advertisement
New Zealand markets closed

  • NZX 50

    11,755.17
    +8.59 (+0.07%)
     

  • NZD/USD

    0.6021
    -0.0013 (-0.21%)
     

  • NZD/EUR

    0.5584
    -0.0010 (-0.18%)
     

  • ALL ORDS

    8,022.70
    +28.50 (+0.36%)
     

  • ASX 200

    7,749.00
    +27.40 (+0.35%)
     

  • OIL

    78.20
    -1.06 (-1.34%)
     

  • GOLD

    2,366.90
    +26.60 (+1.14%)
     

  • NASDAQ

    18,161.18
    +47.72 (+0.26%)
     

  • FTSE

    8,433.76
    +52.41 (+0.63%)
     

  • Dow Jones

    39,512.84
    +125.08 (+0.32%)
     

  • DAX

    18,772.85
    +86.25 (+0.46%)
     

  • Hang Seng

    18,963.68
    +425.87 (+2.30%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

  • NZD/JPY

    93.7530
    -0.0150 (-0.02%)
     

Where Will Biogen Be in 5 Years?

Cory Renauer, The Motley Fool
·4-min read
Where Will Biogen Be in 5 Years?

Biogen (NASDAQ: BIIB) investors recently received an unwelcome surprise from an important government agency. The phrase "coverage with evidence development" (CED) might not sound too serious, but these words from the Centers for Medicare & Medicaid Services (CMS) were heavy enough to put Biogen's stock price under pressure on Wednesday, Jan. 12, 2022. The CMS decision was tough on Biogen stock price in the short term, but what do the next five years have in store?

Continue reading